Acute Myeloid Leukaemia
- Graham H. JacksonAffiliated withDepartment of Haematology, Royal Victoria Infirmary Email author
- , Penelope R. A. TaylorAffiliated withDepartment of Haematology, Royal Victoria Infirmary
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Acute myeloid leukaemia (AML) is a disease of the elderly (median age at presentation 64 years). The outcome in older patients with AML is much worse than that for similarly treated younger patients. Older patients have a high incidence of recognised poor prognostic features (poor performance status, unfavourable cytogenetics, CD34 positive phenotype, raised serum lactate dehydrogenase levels and increased incidence of multidrug resistance protein expression). In addition, treatment is less well tolerated as there is an increased incidence of comorbidity in the elderly.
The outlook for most patients is poor (4% survival at 5 years). However, it is possible to select a group of patients who are fit, with no pre-existing problems and good performance status who will respond well to intensive chemotherapy, and these patients should be treated aggressively. Less intensive treatment is probably more suitable for patients not fitting these criteria. Patients and their relatives should be counselled appropriately as to the prognosis of AML, the choices of treatment available and that intensive regimens are not an appropriate choice for many patients.
- Acute Myeloid Leukaemia
Drugs & Aging
Volume 19, Issue 8 , pp 571-581
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors